CTXR vs. JSPR, ANRO, SKYE, DBVT, IMUX, CTOR, GALT, INZY, ABOS, and ENTX
Should you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Jasper Therapeutics (JSPR), Alto Neuroscience (ANRO), Skye Bioscience (SKYE), DBV Technologies (DBVT), Immunic (IMUX), Citius Oncology (CTOR), Galectin Therapeutics (GALT), Inozyme Pharma (INZY), Acumen Pharmaceuticals (ABOS), and Entera Bio (ENTX). These companies are all part of the "pharmaceutical products" industry.
Citius Pharmaceuticals vs.
Jasper Therapeutics (NASDAQ:JSPR) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
In the previous week, Citius Pharmaceuticals had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 3 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.42 beat Citius Pharmaceuticals' score of -0.75 indicating that Jasper Therapeutics is being referred to more favorably in the media.
79.9% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 2.7% of Jasper Therapeutics shares are owned by insiders. Comparatively, 12.1% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Jasper Therapeutics has a beta of 2.11, indicating that its stock price is 111% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.
Citius Pharmaceuticals' return on equity of -51.69% beat Jasper Therapeutics' return on equity.
Citius Pharmaceuticals received 167 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 90.00% of users gave Jasper Therapeutics an outperform vote while only 62.54% of users gave Citius Pharmaceuticals an outperform vote.
Jasper Therapeutics currently has a consensus target price of $64.44, indicating a potential upside of 979.47%. Citius Pharmaceuticals has a consensus target price of $54.50, indicating a potential upside of 2,870.03%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Jasper Therapeutics.
Summary
Citius Pharmaceuticals beats Jasper Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Citius Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CTXR) was last updated on 2/21/2025 by MarketBeat.com Staff
Free CTXR Stock Alerts